Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the effect of the investigational agent tivozanib
on the control of the tumor growth in hepatocellular (liver) cancer. The investigators also
plan to collect information on the likelihood to develop side effects while on this
treatment. Tivozanib is an oral medication (pill) taken once a day. This medication is
designed to stop the tumor from developing new blood vessels.